In a woman with a pathogenic CHEK2 mutation and a sister with invasive lobular carcinoma, what percentage reduction in breast cancer risk is achieved by bilateral risk‑reducing salpingo‑oophorectomy?

Oophorectomy Does NOT Reduce Breast Cancer Risk in CHEK2 Carriers

Risk-reducing salpingo-oophorectomy (RRSO) is NOT recommended for CHEK2 carriers based on their mutation status alone, as there is no established evidence that it reduces breast cancer risk in this population. 1

Key Guideline Recommendations

The 2023 ACMG guidelines explicitly state: "There is no evidence for an increased risk for ovarian cancer in CHEK2 heterozygotes. Consequently, risk-reducing salpingo-oophorectomy is not recommended based on CHEK2 status; however, as always, it may be indicated based on family history." 1

This is a critical distinction from BRCA1/2 carriers, where RRSO has demonstrated breast cancer risk reduction (though even in BRCA carriers, the evidence is mixed and the magnitude of benefit is debated) 2.

Why CHEK2 is Different from BRCA

CHEK2 mutations confer moderate breast cancer risk (not high-risk like BRCA1/2), and the mechanism does not involve hormone-dependent pathways in the same way. The protective effect of oophorectomy seen in BRCA carriers—particularly BRCA1—relates to removing hormonal stimulation in high-risk, hormone-sensitive breast tissue. This mechanism does not apply to CHEK2 carriers with the same strength of evidence.

The Polish Study Context

While one 2022 Polish study 3 showed improved survival in CHEK2 carriers with breast cancer who had oophorectomy (15-year survival 86.3% vs 72.1%, HR 0.59), this was a treatment study in women already diagnosed with breast cancer, not a prevention study in unaffected carriers. This addresses secondary prevention/treatment outcomes, not primary prevention—which is what your question asks about.

Important caveats about this study:

• Oophorectomies were performed "for treatment of breast cancer or for benign conditions"—not as risk-reducing surgery
• This was survival after diagnosis, not incidence reduction
• The benefit may reflect treatment of hormone-receptor-positive tumors rather than primary prevention

Clinical Algorithm for Your Patient

For a CHEK2 carrier with a sister who has invasive lobular carcinoma:

1. Do NOT recommend RRSO based on CHEK2 status alone 1

2. Perform comprehensive risk assessment using:

   • Family history (sister with ILC is relevant)
   • Risk modeling tools like CanRisk 1
   • Personal risk factors

3. If family history alone (independent of CHEK2) warrants consideration:

   • RRSO may be discussed based on family history criteria
   • But the CHEK2 mutation itself does not add to the indication

4. Focus breast cancer risk reduction on:

   • Enhanced surveillance (annual mammography + MRI based on risk assessment) 1
   • Potentially risk-reducing mastectomy if personalized risk is sufficiently elevated 1
   • Modifiable risk factors

The Bottom Line on Percentage Reduction

There is no established percentage reduction in breast cancer risk from oophorectomy specifically for CHEK2 carriers. The guideline evidence does not support this intervention for primary prevention in this population, and extrapolating BRCA data to CHEK2 carriers is inappropriate given the different genetic mechanisms and risk profiles 1, 4.

Your patient's management should be driven by her overall breast cancer risk (incorporating both CHEK2 and family history) rather than assuming RRSO will provide measurable breast cancer risk reduction.